This test is most useful if any of these apply to you.
An unexpected alpha-ketoadipic acid result needs the rest of the urine organic acid profile to make sense. An inherited problem in amino acid breakdown is one possible explanation, but a high value alone cannot establish its cause or whether it has consequences for your health.
This acid has an established place within specialist investigations of rare metabolic disorders. Using it to assess mitochondrial health, guide supplements or track healthy aging remains exploratory. Those uses have no validated treatment target or demonstrated benefit from routine screening.
Proteins are made of smaller building blocks called amino acids. Your body produces alpha-ketoadipic acid while breaking down lysine, hydroxylysine and tryptophan. Lab reports also call it 2-oxoadipic acid.
An enzyme complex processes the acid inside mitochondria. Mitochondria are compartments in your cells that help turn fuel into usable energy. The DHTKD1 gene provides instructions for one component of this complex. When its activity is impaired, alpha-ketoadipic acid and related compounds can accumulate.
The standard urine method uses gas chromatography-mass spectrometry, or GC-MS. It separates organic acids and identifies them by their chemical signatures. The amount is reported relative to urine creatinine. Creatinine is a waste product related to muscle metabolism, and dividing by it reduces the effect of urine dilution.
The result describes how much of this acid reaches your urine relative to creatinine. It isn't a direct measurement of enzyme activity, energy production or mitochondrial function throughout your body.
A well-described cause of increased urinary alpha-ketoadipic acid is alpha-aminoadipic and alpha-ketoadipic aciduria. This inherited biochemical condition can result from disease-causing changes in both copies of DHTKD1. Urinary alpha-aminoadipic acid also rises, and alpha-hydroxyadipic acid may rise with it. Plasma alpha-aminoadipic acid can provide supporting evidence.
Reports include children with developmental delay or seizures and people with the same biochemical pattern who remain healthy. Healthy siblings carrying the same DHTKD1 variants as an affected relative have also been described. That makes the relationship between this biochemical defect and neurological symptoms uncertain.
The isolated DHTKD1-related pattern can be benign. But an isolated high urine value cannot establish that you have this condition, and it cannot establish that the finding is harmless. Symptoms, companion results and molecular confirmation determine how the pattern is interpreted.
The DLD gene provides instructions for another component of the enzyme complex. This component is also used by enzymes involved in processing sugar-derived fuel, other amino acids and intermediates in energy production. DLD deficiency can therefore disrupt several processes at once.
Urine findings can include lactic acid, alpha-ketoglutaric acid and branched-chain keto acids. These last compounds form during the breakdown of leucine, isoleucine and valine. Alpha-ketoadipic and alpha-hydroxyadipic acids have been detected in some people with DLD deficiency, but they aren't consistently present.
DLD deficiency can cause neurological illness, liver dysfunction and low blood sugar. Episodes may be triggered by infection or fasting. The urine pattern varies between people and can become less apparent between episodes, so a normal result while you're well doesn't exclude the condition.
A separate report described abnormal urinary metabolites from the same breakdown pathway in a person with disease-causing changes in SLC25A21. This gene supplies a transporter that carries the acid into mitochondria. That person had severe nerve and muscle disease resembling spinal muscular atrophy. The finding comes from a single reported case supported by laboratory experiments; it doesn't establish nerve damage as the explanation for an otherwise unexplained high result.
An exploratory study of people with type 2 diabetes found higher urinary oxoadipic acid in those with diabetic kidney disease than in those without it. It was included in a combined urine metabolite score. The researchers used a different analytical method called LC-MS/MS, so the study's measurements aren't directly interchangeable with routine GC-MS results.
The combined score statistically accounted for part of the association between urinary interleukin-18 and kidney disease. Interleukin-18 is an immune signal involved in inflammation. That finding applies to the entire score, not to this acid alone. The study captured one point in time and cannot establish that the acid causes kidney damage or predicts future disease.
Urine albumin-to-creatinine ratio and blood-based eGFR remain the established tests for assessing diabetic kidney disease. Whether adding alpha-ketoadipic acid improves decisions about your care hasn't been established.
Repeated profiles can help establish whether an abnormal pattern persists or appears during particular episodes. There is no validated amount of change in urinary alpha-ketoadipic acid that indicates better mitochondrial health in a healthy adult. A stable result also cannot establish that all the relevant enzymes are functioning normally.
Alpha-Ketoadipic Acid is best interpreted alongside these tests.
Alpha-Ketoadipic Acid is included in these pre-built panels.
See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.
90 biomarkers